FLEX: A heparin-binding fusion partner engineered from fibroblast growth factor 1 to enhance protein expression, solubility and purity

The paper introduces FLEX, a compact, engineered fusion tag derived from fibroblast growth factor 1 that significantly enhances the expression, solubility, and high-stringency purification of challenging recombinant proteins across both bacterial and mammalian systems.

The Gist

Imagine you are trying to build a complex piece of furniture, like a delicate glass table, but the instructions are missing, the screws are rusty, and the wood keeps snapping in half. This is what scientists face when they try to create "recombinant proteins" (man-made versions of biological molecules) in a lab. Many of these proteins are unstable, clump together like wet sand, or are so toxic to the bacteria making them that they kill the factory before the job is done.

For years, scientists have used "fusion tags" to help. Think of these tags as training wheels or handlebars attached to the fragile protein. They help the protein stay upright (soluble) and give the scientists a handle to grab onto for purification. But existing handles have flaws: some are too big and get in the way, some are weak and break, and some are sticky in a messy way that grabs onto unwanted junk.

Enter FLEX.

What is FLEX?

FLEX is a new, super-smart "handle" engineered by scientists at the University of Liverpool. It is a small, compact piece of protein (about 15.5 kilodaltons) that was built by taking a natural protein called FGF1 and giving it a major upgrade.

Think of natural FGF1 as a rusty, wobbly ladder. It's great at grabbing onto a specific wall (heparin), but it's so unstable that it falls apart if you look at it wrong. The scientists took this ladder and:

1. Reinforced the rungs: They swapped out weak, rusty parts for strong, stable ones.
2. Smoothed the edges: They removed jagged bits that caused the ladder to get stuck in other things.
3. Added extra grip: They made the part that grabs the wall even stickier, so it holds on tight even when you try to wash away the dirt.

The result is FLEX: a sturdy, high-grip handle that doesn't just hold the protein; it actually helps the protein stay calm and folded correctly while it's being built.

How Does It Work? The "Velcro vs. Super-Glue" Analogy

Most protein purification methods are like using Velcro. You stick the protein to a column, wash away the dust, and then pull it off. But sometimes, the Velcro isn't strong enough, so the protein falls off with the dust, or the dust sticks to the protein and you can't get it clean.

FLEX uses Super-Glue (specifically, a very strong attraction to a material called heparin).

• The Wash: Because FLEX sticks so tightly to the heparin column, scientists can wash the column with a very strong "detergent" (high salt water) that would knock everything else off.
• The Result: All the junk (contaminants) falls off, but FLEX (and the protein it's holding) stays stuck. When they finally want to release the protein, they use an even stronger solution to break the glue.

This means you get a pure product in a single step, without needing to run the protein through multiple expensive filters.

The "Magic" of FLEX: It Works Everywhere

The most surprising part of this discovery is that FLEX works in two very different "factories":

1. The Bacterial Factory (E. coli): This is the cheap, fast, but messy factory. Many proteins get stuck or die here. FLEX acted like a bodyguard, shielding toxic proteins (like bacterial weapons from Pseudomonas) and helping them fold correctly so they could be harvested in large quantities.
2. The Mammalian Factory (Human cells): This is the high-end, expensive factory that makes complex proteins. Usually, scientists use small tags here because big tags interfere with the cell's delicate machinery. FLEX, despite being a "handle," was small enough and smart enough to work here too. In fact, it outperformed the "gold standard" tags (like Myc and Strep) for difficult proteins, yielding more product and higher purity.

Why Should You Care?

Imagine you are a doctor trying to develop a new drug to fight cancer or a virus. To do this, you need to study the "bad guys" (proteins) in detail. But if you can't make enough of them, or if they are broken when you get them, you can't study them.

FLEX is like a universal key that unlocks the ability to make these difficult proteins.

• It helps scientists make toxic bacterial proteins safe to study.
• It helps make human signaling proteins (like TRIB3, which is involved in cancer and metabolism) that were previously impossible to get in pure form.
• It saves time and money by cleaning up the protein in one step instead of five.

The Bottom Line

FLEX is a clever piece of bio-engineering that turns a fragile, unstable protein into a robust, high-performance tool. It's like taking a flimsy cardboard box and turning it into a reinforced steel crate that can carry delicate glassware across a bumpy road without breaking. By making it easier to produce and purify these difficult proteins, FLEX opens the door for faster drug discovery, better understanding of diseases, and more efficient biotechnology.

Technical Summary

1. Problem Statement

The expression and purification of recombinant proteins, particularly those that are aggregation-prone, unstable, or cytotoxic, remain a major bottleneck in structural biology, enzymology, and biopharmaceutical development.

• Limitations of Current Tags:
  • Small Affinity Tags (e.g., His-tag): Offer rapid purification but lack solubility enhancement and often suffer from low stringency, leading to co-purification of host contaminants, especially in complex mammalian lysates.
  • Large Solubility Tags (e.g., MBP, GST, SUMO): Improve solubility and yield but are large (26–42 kDa), potentially interfering with protein function or structural characterization. They often require additional downstream processing (tag removal) and have slower binding/elution kinetics.
  • Native Heparin-Binding Proteins: While heparin affinity chromatography is a high-stringency method, native heparin-binding proteins (like wild-type FGF1) are often unstable, prone to aggregation, and difficult to express in high yields, limiting their utility as fusion handles.

2. Methodology

The authors engineered a novel fusion tag named FLEX (FGF1-Like Engineered eXpression tag) by rationally redesigning human Fibroblast Growth Factor 1 (FGF1).

• Design Strategy:

  • Scaffold Selection: Used human FGF1 (residues 17–152) due to its well-characterized $\beta$-trefoil fold and broad heparin-binding capability.
  • Computational & Structural Engineering: Utilized structure-guided redesign (based on PDB: 1JQZ) and computational tools (PROSS, AlphaFold2, MODELLER) to introduce specific amino acid substitutions.
  • Key Modifications:
    • Stabilization: Reduced exposed hydrophobic residues and removed flexible, protease-susceptible regions.
    • Electrostatic Optimization: Expanded the electropositive surface area to enhance heparin affinity while preserving the canonical heparin-binding interface (conserved Lys/Arg residues).
    • Truncation: Removed disordered N-terminal (1–16) and distal C-terminal residues.
  • Construct Design: FLEX was cloned into pET-28a(+) for bacterial expression and pTWIST CMV for mammalian expression, featuring an N-terminal 6×His tag, a TEV protease cleavage site, and the FLEX tag.

• Experimental Validation:

  • Biophysical Characterization: Isothermal Titration Calorimetry (ITC) for heparin binding affinity ($K_D$); Differential Scanning Fluorimetry (DSF) for thermal and chemical stability (urea resistance).
  • Expression Systems: Tested in E. coli (BL21(DE3)) and mammalian HEK293T cells.
  • Purification: Compared Heparin Affinity Chromatography (HAC) against Immobilized Metal Affinity Chromatography (IMAC) and other standard tags (MBP, GST, Myc, Strep).
  • Target Proteins: Challenging targets included Pseudomonas aeruginosa virulence factors (ExoU, ExoS, LasB), L-lactate oxidase, and the mammalian pseudokinase TRIB3.

3. Key Contributions

• Creation of FLEX: A compact (15.5 kDa), dual-function fusion tag that integrates intrinsic protein stabilization with high-affinity heparin binding.
• Rational Engineering: Demonstrated that stabilizing mutations can be introduced into a heparin-binding scaffold without disrupting the binding interface, actually enhancing affinity through surface electrostatic optimization.
• Cross-Platform Utility: Validated FLEX's efficacy in both prokaryotic (E. coli) and eukaryotic (HEK293T) systems, a rare feat for a single fusion tag.

4. Key Results

A. Biophysical Properties of FLEX

• Enhanced Stability: FLEX showed a melting temperature ($T_m$) of 74.1°C, a 22°C increase over wild-type FGF1 (52.1°C). It remained stable in 6 M urea, whereas WT FGF1 unfolded completely.
• Superior Heparin Affinity: ITC analysis revealed FLEX binds heparin with a $K_D$ of ~0.5 µM, significantly tighter than WT FGF1 ($K_D$ ~3.6 µM).
• High-Stringency Purification: Due to high affinity, FLEX-tagged proteins could be washed with 1 M NaCl to remove non-specific contaminants and eluted at 1.5–2.0 M NaCl, a condition that removes most host proteins.

B. Performance in E. coli (Bacterial Expression)

• Yield Improvement: FLEX expression yields increased from 0.5 mg/L (WT FGF1) to **4 mg/L** via IMAC.
• Difficult Targets:
  • ExoU (Cytotoxin): Conventional tags (His, MBP, GST) failed to yield soluble full-length protein or resulted in heavy contamination. FLEX enabled single-step purification of full-length, active ExoU.
  • ExoS (Multidomain Enzyme): FLEX-HAC yielded apparent homogeneity in a single step, whereas IMAC required Size-Exclusion Chromatography (SEC) and still showed background contamination.
  • LasB (Protease): Typically forms inclusion bodies or is toxic; FLEX enabled recovery of ~0.5 mg/L of soluble, pure protein.
• Activity Retention: Enzymatic assays confirmed that FLEX fusion did not impair the catalytic activity of ExoU, ExoS, or LasB.

C. Performance in Mammalian Systems

• PKA Purification: In HEK293T cells, FLEX-HAC yielded a strikingly pure preparation of Protein Kinase A (PKA) in a single step, whereas IMAC resulted in significant co-purification of host proteins.
• TRIB3 (Pseudokinase): A notoriously difficult target. FLEX-tagged TRIB3 showed significantly higher recovery and purity compared to gold-standard Myc and Strep tags, which often fail to yield sufficient material for biochemical analysis.

5. Significance and Impact

• Solving the "Intractable" Protein Problem: FLEX provides a practical solution for expressing proteins that are toxic, unstable, or aggregation-prone, which are often refractory to standard pipelines.
• Workflow Simplification: By combining solubility enhancement with high-stringency affinity purification, FLEX often eliminates the need for multi-step purification or tag removal, reducing time and labor.
• Cost-Effectiveness: Unlike antibody-based tags (Myc, FLAG) or Strep-tags which require expensive, often single-use resins, heparin resins are chemically robust, regenerable with high-salt washes, and reusable.
• Versatility: The ability of FLEX to function effectively in both bacterial and mammalian systems allows for seamless transition from initial expression screening to functional validation in eukaryotic contexts without construct redesign.
• Future Applications: FLEX is positioned as a valuable tool for structural biology, inhibitor screening (e.g., for TRIB3), and the production of therapeutic targets, bridging the gap between academic research and industrial protein manufacturing.

In conclusion, FLEX represents a significant advancement in recombinant protein technology, offering a modular, stable, and high-affinity platform that overcomes the trade-offs inherent in existing fusion tag strategies.